Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

le suspension), under development for the treatment of advanced prostate cancer; and oxybutynin topical gel, under development for overactive bladder.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of clinical studies, product development efforts and FDA or other regulatory agency approvals or actions; whether the results of clinical trials for oxybutynin topical gel and other information will be sufficient to support approval by FDA and other regulatory authorities; delays regarding the regulatory approval process, including the timing and scope of approval received, if any; market acceptance and continued demand for Watson's products, including oxybutynin topical gel, if approved; our ability to successfully defend and/or enforce our patents and other intellectual property rights against third pa
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ... per share, net to the seller in cash, without ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ... reductions in body fat content and preserved lean ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on ... results is scheduled for release after the close of ... Management will hold a conference call to discuss ... quarter and twelve months ended December 31, 2013 on ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... cancers and infectious diseases, announced today that Dr. J. Joseph ... the Cowen & Co. 31st Annual Health Care Conference being ... Boston, MA. Inovio Presentation: March 9, 2011 ...
... ALTO, Calif., Feb. 23, 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: ... make a presentation at the Citi 2011 Global Health Care ... 9:30 a.m. Eastern Time.  Bruce Cozadd, the company,s chairman and ... A live webcast of the presentation may be accessed from ...
Cached Medicine Technology:Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference 2Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... similar medicines pose big stomach risks, study notes ... of patients don,t tell their doctors that they take ... potentially dangerous omission, a new study has found. , ... medicine intake, it is no wonder that adverse events ...
... four out of ten HIV positive African-American men could be putting ... in the latest UK-based Journal of Advanced Nursing. , A ... that many of the 40 to 65 year-olds were engaging in ... oral sex, with 25 per cent having unprotected vaginal sex and ...
... contribute to heart attack, stroke and dementia, likely also ... researchers say. , Homocysteine levels rise when folic acid ... are often poor in folate-rich fruits, tomatoes, vegetables and ... the Medical College of Georgia. , Scientists want to ...
... Donates Hotel Points to Benefit More Transplant Patients and Family ... ... The National Foundation for,Transplants (NFT) announced today that it will extend free ... to,pre- and post-transplant care through an expansion of its Home Away From,Home ...
... Winners Announced at Annual ASRM Meeting, ... won Ferring,Pharmaceuticals, national 2007 My Little Miracle ... the births of their ,little miracles,children born ... fertility treatments.,The fourth annual contest celebrated the ...
... Oct. 15 Edwards Lifesciences,Corporation (NYSE: EW ), ... cardiovascular disease, plans to announce its operating,results for the ... on,Monday, October 22, 2007 and will host a conference ... results. To participate in the conference call, dial ...
Cached Medicine News:Health News:Many Patients Don't Report Use of OTC Pain Drugs 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 3Health News:Older African-American men with HIV often have sex without condoms 2Health News:Impact of elevated homocysteine levels on vision under study 2Health News:Impact of elevated homocysteine levels on vision under study 3Health News:National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families 2Health News:National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families 3Health News:Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest 2Health News:Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest 3Health News:Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest 4Health News:Edwards Lifesciences to Host Earnings Conference Call on October 22, 2007 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: